- Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
-
Miseon Lee, In Ah Park, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee
-
J Pathol Transl Med. 2019;53(3):180-187. Published online March 11, 2019
-
DOI: https://doi.org/10.4132/jptm.2019.02.08
-
-
7,922
View
-
202
Download
-
17
Web of Science
-
17
Crossref
-
 Abstract
 PDF
- Background
Most triple-negative breast cancers (TNBCs) have a high histologic grade, are associated with high endoplasmic stress, and possess a high frequency of TP53 mutations. TP53 missense mutations lead to the production of mutant p53 protein and usually show high levels of p53 protein expression. Tumor-infiltrating lymphocytes (TILs) accumulate as part of the anti-tumor immune response and have a strong prognostic and predictive significance in TNBC. We aimed to elucidate the association between p53 expression and the amount of TILs in TNBC.
Methods
In 678 TNBC patients, we evaluated TIL levels and expression of endoplasmic stress molecules. Immunohistochemical examination of p53 protein expression was categorized into three groups: no, low, and high expression.
Results
No, low, and high p53 expression was identified in 44.1% (n = 299), 20.1% (n = 136), and 35.8% (n = 243) of patients, respectively. Patients with high p53 expression showed high histologic grade (p < .001), high TIL levels (p = .009), and high expression of endoplasmic reticulum stress-associated molecules (p-eIF2a, p = .013; XBP1, p = .007), compared to patients with low p53 expression. There was no significant difference in disease-free (p = .406) or overall survival rates (p = .444) among the three p53 expression groups.
Conclusions
High p53 expression is associated with increased expression of endoplasmic reticulum stress molecules and TIL influx.
-
Citations
Citations to this article as recorded by  - The search for a TNBC vaccine: the guardian vaccine
Cory Fines, Helen McCarthy, Niamh Buckley
Cancer Biology & Therapy.2025;[Epub] CrossRef - Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple‐negative breast cancer
Meejeong Kim, Miseon Lee, Ahwon Lee, Byung‐Ock Choi, Woo‐Chan Park, Sung Hun Kim, Jieun Lee, Jun Kang
Histopathology.2025;[Epub] CrossRef - Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Rupert Bartsch, Gabriel Rinnerthaler, Edgar Petru, Daniel Egle, Michael Gnant, Marija Balic, Thamer Sliwa, Christian Singer
Wiener klinische Wochenschrift.2024; 136(11-12): 347. CrossRef - Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
Sotiris Loizides, Anastasia Constantinidou
Frontiers in Genetics.2023;[Epub] CrossRef - Prognostic benefit of TILs independent of clinicopathological and molecular factors
Koen Brummel, Anneke L. Eerkens, Marco de Bruyn, Hans W. Nijman
British Journal of Cancer.2023; 129(5): 737. CrossRef - Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner
Xinyu Zhou, Abel Soto-Gamez, Fleur Nijdam, Rita Setroikromo, Wim J. Quax
Frontiers in Oncology.2022;[Epub] CrossRef - New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma
Andrii Puzyrenko, Chandler S Cortina, Julie M Jorns
International Journal of Surgical Pathology.2022; 30(7): 728. CrossRef - Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
Shengnan Sha, Luyi Si, Xinrui Wu, Yuanbiao Chen, Hui Xiong, Ying Xu, Wangrui Liu, Haijun Mei, Tao Wang, Mei Li
Frontiers in Immunology.2022;[Epub] CrossRef - p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer
Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang
Cancer Investigation.2022; 40(10): 879. CrossRef - Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Arpita Poddar, Sushma R. Rao, Prashanth Prithviraj, George Kannourakis, Aparna Jayachandran
Current Oncology.2022; 29(10): 6847. CrossRef - The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting
Natsuki Furukawa, Vered Stearns, Cesar A. Santa-Maria, Aleksander S. Popel
Expert Opinion on Therapeutic Targets.2022; 26(12): 1041. CrossRef - Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions
Katarzyna Dominika Sluzalska, Jakub Slawski, Martyna Sochacka, Agata Lampart, Jacek Otlewski, Malgorzata Zakrzewska
Cytokine & Growth Factor Reviews.2021; 57: 93. CrossRef - Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study
Hiu Yee Kwan, Qinghua Xu, Ruihong Gong, Zhaoxiang Bian, Chih-Chang Chu
Frontiers in Oncology.2021;[Epub] CrossRef - Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
Marie Colombe Agahozo, Marcel Smid, Ronald van Marion, Dora Hammerl, Thierry P. P. van den Bosch, Mieke A. M. Timmermans, Chayenne J. Heijerman, Pieter J. Westenend, Reno Debets, John W. M. Martens, Carolien H. M. van Deurzen
Biology.2021; 10(8): 768. CrossRef - With Our Powers Combined
Lawrence Kasherman, Katherine Karakasis, Amit M. Oza
The Cancer Journal.2021; 27(6): 511. CrossRef The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer
Li Chen, Xiangyi Kong, Chengrui Yan, Yi Fang, Jing Wang
OncoTargets and Therapy.2020; Volume 13: 1397. CrossRefBiomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer
Xenia Elena Bacinschi, Anca Zgura, Inga Safta, Rodica Anghel
Cancer Management and Research.2020; Volume 12: 11965. CrossRef
|
E-submission
